Qualification of impurities based on metabolite data.

Area of Science:

• Pharmaceutical Science
• Drug Metabolism and Pharmacokinetics
• Toxicology

Background:

• Current regulatory guidance (ICH Q3A (R2), Q3B (R2)) considers impurities that are also significant metabolites qualified.
• However, specific data requirements and definitions for
• significant metabolite
• are lacking, leading to potential delays and increased costs in drug development.

Purpose of the Study:

• To define criteria for qualifying impurities as significant metabolites.
• To propose methodologies to avoid separate toxicity studies for impurity qualification.
• To reduce costs, animal usage, and drug development timelines.

Main Methods:

• Proposed two complementary approaches for impurity qualification based on metabolite data.
• Approach 1: Demonstrate impurity formation via metabolism in animals/humans (plasma exposure or urinary excretion).
• Approach 2: Ensure animal exposure to the impurity/metabolite is equal to or greater than human exposure.
• Consideration of maximum theoretical concentration/amount (MTC/MTA) for impurity/metabolite.

Main Results:

• Justification for impurity qualification is supported if metabolite concentration/amount in animals or humans is similar to the impurity.
• Methodologies provided to demonstrate metabolic formation and comparative exposure levels.
• Recommendations for estimating MTC and MTA are presented.

Conclusions:

• The proposed approaches offer a framework for qualifying impurities as significant metabolites.
• Implementation can streamline drug development by reducing the need for additional toxicity studies.
• This strategy benefits drug development by saving time, resources, and reducing animal testing.